Hamdy S - Search Results

1

Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124.

Molavi O, Ma Z, Hamdy S, Lavasanifar A, Samuel J. Molavi O, et al. Among authors: hamdy s. Immunopharmacol Immunotoxicol. 2009 Jun;31(2):214-21. doi: 10.1080/08923970802380452. Immunopharmacol Immunotoxicol. 2009. PMID: 18798092

2

Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles.

Hamdy S, Elamanchili P, Alshamsan A, Molavi O, Satou T, Samuel J. Hamdy S, et al. J Biomed Mater Res A. 2007 Jun 1;81(3):652-62. doi: 10.1002/jbm.a.31019. J Biomed Mater Res A. 2007. PMID: 17187395

3

Pharmaceutical analysis of synthetic lipid A-based vaccine adjuvants in poly (D,L-lactic-co-glycolic acid) nanoparticle formulations.

Hamdy S, Haddadi A, Somayaji V, Ruan D, Samuel J. Hamdy S, et al. J Pharm Biomed Anal. 2007 Aug 15;44(4):914-23. doi: 10.1016/j.jpba.2007.03.010. Epub 2007 Mar 19. J Pharm Biomed Anal. 2007. PMID: 17590559

4

Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.

Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, Samuel J. Molavi O, et al. Among authors: hamdy s. Immunol Cell Biol. 2008 Aug-Sep;86(6):506-14. doi: 10.1038/icb.2008.27. Epub 2008 Apr 8. Immunol Cell Biol. 2008. PMID: 18392040

5

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.

Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A. Hamdy S, et al. Vaccine. 2008 Sep 15;26(39):5046-57. doi: 10.1016/j.vaccine.2008.07.035. Epub 2008 Aug 3. Vaccine. 2008. PMID: 18680779

6

The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.

Alshamsan A, Hamdy S, Samuel J, El-Kadi AO, Lavasanifar A, Uludağ H. Alshamsan A, et al. Among authors: hamdy s. Biomaterials. 2010 Feb;31(6):1420-8. doi: 10.1016/j.biomaterials.2009.11.003. Epub 2009 Nov 13. Biomaterials. 2010. PMID: 19913908

7

Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy.

Molavi O, Mahmud A, Hamdy S, Hung RW, Lai R, Samuel J, Lavasanifar A. Molavi O, et al. Among authors: hamdy s. Mol Pharm. 2010 Apr 5;7(2):364-74. doi: 10.1021/mp900145g. Mol Pharm. 2010. PMID: 20030320

8

Validation of bone marrow derived dendritic cells as an appropriate model to study tumor-mediated suppression of DC maturation through STAT3 hyperactivation.

Alshamsan A, Hamdy S, Das S, Lavasanifar A, Samuel J, El-Kadi AO. Alshamsan A, et al. Among authors: hamdy s. J Pharm Pharm Sci. 2010 Feb 2;13(1):21-6. doi: 10.18433/j37598. J Pharm Pharm Sci. 2010. PMID: 20456827 Free article.

9

Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles.

Ghotbi Z, Haddadi A, Hamdy S, Hung RW, Samuel J, Lavasanifar A. Ghotbi Z, et al. Among authors: hamdy s. J Drug Target. 2011 May;19(4):281-92. doi: 10.3109/1061186X.2010.499463. Epub 2010 Jun 30. J Drug Target. 2011. PMID: 20590403

10

STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response.

Alshamsan A, Haddadi A, Hamdy S, Samuel J, El-Kadi AO, Uludağ H, Lavasanifar A. Alshamsan A, et al. Among authors: hamdy s. Mol Pharm. 2010 Oct 4;7(5):1643-54. doi: 10.1021/mp100067u. Epub 2010 Sep 14. Mol Pharm. 2010. PMID: 20804176

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

284 results

Search Page

Filters